Beactica Announces Drug Discovery Research Collaboration with GE Healthcare and Uppsala University
Read time:
Beactica has announced a new research collaboration agreement with GE Healthcare and Uppsala University (Sweden). The collaboration combines Beactica's approach to fragment-based drug discovery and GE Healthcare's Biacore™ technology with enzymology expertise from Uppsala University.
Under the terms of the agreement, the consortium will collaborate to develop the next generation of Biacore™ surface plasmon resonance instruments and applications for fragment-based drug discovery.
The project also aims to identify high-quality leads against a clincally important, undisclosed protein target from Beactica's discovery pipeline. Financial terms of the agreement were not disclosed.
"We look forward to deepening our relationship with GE Healthcare and Uppsala University," said Beactica's CEO, Dr Per Kallblad. "The Biacore technology is a core component of our kinetics-integrated lead discovery platform. Being an active part in the development of next - generation applications from GE Healthcare will enable us to stay at the forefront of our field."
Under the terms of the agreement, the consortium will collaborate to develop the next generation of Biacore™ surface plasmon resonance instruments and applications for fragment-based drug discovery.
The project also aims to identify high-quality leads against a clincally important, undisclosed protein target from Beactica's discovery pipeline. Financial terms of the agreement were not disclosed.
"We look forward to deepening our relationship with GE Healthcare and Uppsala University," said Beactica's CEO, Dr Per Kallblad. "The Biacore technology is a core component of our kinetics-integrated lead discovery platform. Being an active part in the development of next - generation applications from GE Healthcare will enable us to stay at the forefront of our field."
Advertisement
